Acid-suppressing Drugs Pregnancy Asthma Offspring Study
NCT ID: NCT01787435
Last Updated: 2015-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10116 participants
OBSERVATIONAL
2012-06-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To estimate the association between prenatal exposure to proton pump inhibitors (PPIs) and the risk of asthma during childhood.
2. To estimate the association between prenatal exposure to H2-receptor antagonists (H2RAs) and the risk of asthma during childhood.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02276872
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02633293
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
NCT06350032
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT02603068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All women exposed to PPI at any time during pregnancy
Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
Risk of asthma in offspring
Exposure to PPI or H2RA, respectively during pregnancy
No exposure to acid suppressing drugs during pregnancy
All women exposed to H2RA at any time during pregnancy
Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
Risk of asthma in offspring
Exposure to PPI or H2RA, respectively during pregnancy
No exposure to acid suppressing drugs during pregnancy
Pregnant women with no recorded use of acid suppressing drugs
Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risk of asthma in offspring
Exposure to PPI or H2RA, respectively during pregnancy
No exposure to acid suppressing drugs during pregnancy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luis A Garcia Rodriguez, MD
Role: PRINCIPAL_INVESTIGATOR
CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research )
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9612N00018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.